|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
EP1690935A3
(en)
|
1990-01-12 |
2008-07-30 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
ES2246502T3
(es)
|
1990-08-29 |
2006-02-16 |
Genpharm International, Inc. |
Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
|
|
US5641870A
(en)
|
1995-04-20 |
1997-06-24 |
Genentech, Inc. |
Low pH hydrophobic interaction chromatography for antibody purification
|
|
CA2219361C
(en)
|
1995-04-27 |
2012-02-28 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
WO1996034096A1
(en)
|
1995-04-28 |
1996-10-31 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
EP1972194A1
(en)
|
1996-12-03 |
2008-09-24 |
Amgen Fremont Inc. |
Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
|
|
WO1999029888A1
(en)
|
1997-12-05 |
1999-06-17 |
The Scripps Research Institute |
Humanization of murine antibody
|
|
KR101704734B1
(ko)
|
2005-07-01 |
2017-02-09 |
이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. |
예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
|
|
WO2010036959A2
(en)
|
2008-09-26 |
2010-04-01 |
Dana-Farber Cancer Institute |
Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
|
|
KR101712576B1
(ko)
|
2008-11-10 |
2017-03-06 |
버텍스 파마슈티칼스 인코포레이티드 |
Atr 키나제의 억제제로서 유용한 화합물
|
|
MX356367B
(es)
|
2008-12-09 |
2018-05-25 |
Genentech Inc |
Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
|
|
PL3354650T3
(pl)
|
2008-12-19 |
2022-06-13 |
Vertex Pharmaceuticals Incorporated |
Związki przydatne jako inhibitory kinazy atr
|
|
WO2010089411A2
(en)
|
2009-02-09 |
2010-08-12 |
Universite De La Mediterranee |
Pd-1 antibodies and pd-l1 antibodies and uses thereof
|
|
EP3279215B1
(en)
|
2009-11-24 |
2020-02-12 |
MedImmune Limited |
Targeted binding agents against b7-h1
|
|
WO2011143423A2
(en)
|
2010-05-12 |
2011-11-17 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
US9096584B2
(en)
|
2010-05-12 |
2015-08-04 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
US8962631B2
(en)
|
2010-05-12 |
2015-02-24 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
JP2013526538A
(ja)
|
2010-05-12 |
2013-06-24 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Atrキナーゼ阻害剤として有用な化合物
|
|
JP2013526540A
(ja)
|
2010-05-12 |
2013-06-24 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Atrキナーゼ阻害剤として有用な化合物
|
|
JP5836367B2
(ja)
|
2010-05-12 |
2015-12-24 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
Atrキナーゼ阻害剤として有用な化合物
|
|
JP2013529643A
(ja)
|
2010-06-23 |
2013-07-22 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Atrキナーゼ阻害剤として有用なピロロピラジン誘導体
|
|
SG10201408229WA
(en)
|
2010-08-31 |
2015-02-27 |
Genentech Inc |
Biomarkers and methods of treatment
|
|
CA2832100A1
(en)
|
2011-04-05 |
2012-10-11 |
Vertex Pharmaceuticals Incorporated |
Aminopyrazine compounds useful as inhibitors of tra kinase
|
|
JP2014522818A
(ja)
|
2011-06-22 |
2014-09-08 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Atrキナーゼ阻害剤として有用な化合物
|
|
WO2012178123A1
(en)
|
2011-06-22 |
2012-12-27 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
WO2012178125A1
(en)
|
2011-06-22 |
2012-12-27 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
BR112014002353B1
(pt)
|
2011-08-01 |
2022-09-27 |
Genentech, Inc |
Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit
|
|
RU2018147217A
(ru)
|
2011-09-30 |
2019-01-18 |
Вертекс Фармасьютикалз Инкорпорейтед |
Способы получения соединений, которые можно использовать в качестве ингибиторов киназы atr
|
|
IN2014KN00943A
(cg-RX-API-DMAC7.html)
|
2011-09-30 |
2015-08-21 |
Vertex Pharma |
|
|
US8765751B2
(en)
|
2011-09-30 |
2014-07-01 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
AU2012315384B2
(en)
|
2011-09-30 |
2017-08-10 |
Vertex Pharmaceuticals Incorporated |
Treating pancreatic cancer and non-small cell lung cancer with ATR inhibitors
|
|
US8853217B2
(en)
|
2011-09-30 |
2014-10-07 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
EP2776429A1
(en)
|
2011-11-09 |
2014-09-17 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
EP2776421A1
(en)
|
2011-11-09 |
2014-09-17 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
WO2013071090A1
(en)
|
2011-11-09 |
2013-05-16 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
US8841450B2
(en)
|
2011-11-09 |
2014-09-23 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
US8841449B2
(en)
|
2011-11-09 |
2014-09-23 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
BR112014012819B1
(pt)
|
2011-11-28 |
2022-08-16 |
Merck Patent Gmbh |
Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
|
|
CN104582795B
(zh)
|
2012-04-05 |
2018-04-20 |
沃泰克斯药物股份有限公司 |
可用作atr激酶抑制剂的化合物及其组合疗法
|
|
DK2904406T3
(en)
|
2012-10-04 |
2018-06-18 |
Vertex Pharma |
METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE
|
|
US8912198B2
(en)
|
2012-10-16 |
2014-12-16 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
LT3418281T
(lt)
|
2012-12-07 |
2021-01-11 |
Vertex Pharmaceuticals Inc. |
Pirazolo[1,5-a]pirimidinai, naudotini kaip atr kinazės inhibitoriai, skirti vėžinių ligų gydymui
|
|
AR093984A1
(es)
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
|
EP2970288A1
(en)
|
2013-03-15 |
2016-01-20 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
WO2014143240A1
(en)
|
2013-03-15 |
2014-09-18 |
Vertex Pharmaceuticals Incorporated |
Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
|
|
EP2970289A1
(en)
|
2013-03-15 |
2016-01-20 |
Vertex Pharmaceuticals Inc. |
Compounds useful as inhibitors of atr kinase
|
|
US10202454B2
(en)
|
2013-10-25 |
2019-02-12 |
Dana-Farber Cancer Institute, Inc. |
Anti-PD-L1 monoclonal antibodies and fragments thereof
|
|
HUE046727T2
(hu)
|
2013-12-06 |
2020-03-30 |
Vertex Pharma |
Az ATR-kináz inhibitoraként használható vegyület, 2-amino-6-fluoro-N-[5-fluoro-piridin-3-IL]-pirazolo-[1,5-A]-pirimidin-3-karboxamid, ennek elõállítása, különbözõ szilárd formái és ezek radioaktív nyomjelzett származékai
|
|
EP3077393A1
(en)
|
2013-12-06 |
2016-10-12 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
ES2777608T3
(es)
|
2014-06-05 |
2020-08-05 |
Vertex Pharma |
Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útiles como inhibidores de ATR cinasa, la preparación de dicho compuesto y diferentes formas sólidas del mismo
|
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗pd-1抗體類和使用彼等之方法
|
|
KR20170132171A
(ko)
*
|
2015-02-26 |
2017-12-01 |
메르크 파텐트 게엠베하 |
암 치료를 위한 pd1 / pdl1 저해제
|
|
EP3387155A4
(en)
|
2015-12-10 |
2019-06-12 |
Definiens AG |
METHOD FOR THE TREATMENT AND SELECTION OF PATIENTS THAT APPLY TO IMMUNE-ACTED CANCER THERAPY
|